Plasminogen Activator in Bronchoalveolar Fluid

Matsuo, Osamu; Sakai, Tetsuhiro; Bando, Hiroshi; Okada, Kiyotaka; Nakajima, S; Takagi, Ohmi; Izaki, Seiichi

doi:10.1159/000215268

Cited by 32 publications

(16 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The activities of uPA and tPA were performed as described previously [23]. 10% polyacrylamide gel contained 0.55 mg/ml of bovine fibrinogen and 0.056 NIH U/ml of thrombin (Sigma, St. Louis, MO).…”

Section: Zymography Assaymentioning

confidence: 99%

c-Myc is essential for urokinase plasminogen activator expression on hypoxia-induced vascular smooth muscle cells

Hou¹,

Okamoto²,

Okada³

et al. 2007

Cardiovascular Research

View full text Add to dashboard Cite

show abstract

Section: Zymography Assaymentioning

confidence: 99%

c-Myc is essential for urokinase plasminogen activator expression on hypoxia-induced vascular smooth muscle cells

Hou¹,

Okamoto²,

Okada³

et al. 2007

Cardiovascular Research

View full text Add to dashboard Cite

show abstract

“…8 Plasminogen activator activity was measured by the fibrin film method 9 as well as by electrophoretic enzymography. 10 Electrophoretic enzymography was performed with sodium dodecyl sulfatepolyacrylamide gel 11 containing plasminogen-rich fibrin. After electrophoresis, the gel was placed in 2.5% Triton X-100 and washed three times.…”

Section: Resultsmentioning

confidence: 99%

Cerebral plasminogen activator activity in spontaneously hypertensive stroke-prone rats.

Matsuo

Okada

Fukao

et al. 1992

Stroke

View full text Add to dashboard Cite

Background and Purpose:In the spontaneously hypertensive stroke-prone rat, it is unclear whether plasminogen activator plays a role in the development of stroke. The present study was undertaken to investigate brain levels of plasminogen activator activity in spontaneously hypertensive stroke-prone rats and Wistar-Kyoto rats.Methods: Plasminogen activator was purified from the brains of rats of both strains. The purification involved used ammonium sulfate precipitation, gel filtration, a zinc chelate-Sepharose column, and a concanavalin A-Sepharose column. Fraction I (0.15 M KCl-soluble fraction) and fraction II (2 M KCI plus 6 M urea-soluble fraction) were purified from both strains.Results: Total plasminogen activator activity in the original homogenates for fractions I and II derived from spontaneously hypertensive stroke-prone rats was increased to twice the level found in Wistar-Kyoto rats. The final product purified from fractions I and II in both strains of rats revealed single bands of plasminogen activator activity on enzymatic analysis with a molecular weight of 72,000. The purified product had stronger S-2288 amidolytic activity than S-2444 amidolytic activity, and it also displayed fibrin-binding ability.Conclusions: The study demonstrated that there is an increased content of plasminogen activator in the brains of spontaneously hypertensive stroke-prone rats that might be related to the development of stroke.

show abstract

“…The assay of u-PA and t-PA activity was performed as previously described [11]. Briefly, 10% polyacrylamide gel contained 0.55 mg/ml bovine plasminogen-rich fibrinogen (Organon Teknika; Dublin, Ireland) and 0.056 NIH U/ml thrombin (Sigma-Aldrich; St. Louis, MO, USA).…”

Section: Assay Of Fibrinolytic Activity With Zymographymentioning

confidence: 99%

Profibrinolytic effect of Enzamin, an extract of metabolic products from Bacillus subtilis AK and Lactobacillus

Tamura

Okada

Kawao

et al. 2011

J Thromb Thrombolysis

View full text Add to dashboard Cite

Fibrinolytic system impairment contributes to the development of thrombotic disease such as cardiovascular disease and stroke. Therefore, an agent that increases fibrinolytic activity may be useful for the prevention of these diseases. In this study, to explore novel profibrinolytic agents, we examined the profibrinolytic effect of Enzamin, an extract of metabolic products from Bacillus subtilis AK and Lactobacillus in vitro and in vivo. Enzamin directly enhanced plasmin activity generated by tissue-type plasminogen activator (t-PA) by twofold but not by urokinase-type plasminogen activator (u-PA) in vitro, which was measured employing both the chromogenic substrate H-D: -Val-Leu-Lys-pNA (S-2251) and fibrin plate. Enzamin also increased plasmin activity generated by t-PA in the cell lysate and culture medium of endothelial cells, measured by fibrin zymography. Furthermore, the oral administration of a 1% concentration of Enzamin increased plasmin activity generated by t-PA by 1.7-fold but not by u-PA in the euglobulin fraction of mouse plasma. In conclusion, Enzamin has a unique ability to enhance the fibrinolytic activity through an increase in endogenous plasmin activity generated by t-PA released from endothelial cells, and may be a beneficial supplement for the prevention of thrombotic episodes.

show abstract

Plasminogen Activator in Bronchoalveolar Fluid

Cited by 32 publications

References 12 publications

c-Myc is essential for urokinase plasminogen activator expression on hypoxia-induced vascular smooth muscle cells

c-Myc is essential for urokinase plasminogen activator expression on hypoxia-induced vascular smooth muscle cells

Cerebral plasminogen activator activity in spontaneously hypertensive stroke-prone rats.

Profibrinolytic effect of Enzamin, an extract of metabolic products from Bacillus subtilis AK and Lactobacillus

Contact Info

Product

Resources

About